Results 61 to 70 of about 2,670,563 (294)
Медицинский совет, 2021 Introduction. Сombination of alpelisib plus fulvestrant is approved in patients with hormone receptor positive, HER2-negative, PIK3CA-mutated advanced breast cancer (ABC) after progression on hormonotherapy.
D. A. Filonenko +7 more
doaj +1 more source
Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential
FEBS Letters, EarlyView.Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta +3 more
wiley +1 more source
Structural biology helps interpret variants of uncertain significance in genes causing endocrine and metabolic disorders [PDF]
, 2018 Context Variants of uncertain significance (VUSs) lack sufficient evidence, in terms of statistical power or experimental studies, to allow unequivocal determination of their damaging effect.
Sirawit Ittisoponpisan +3 more
core +1 more source
Helicobacter pylori in Diabetic and Non-Diabetic Patients with Dyspepsia
Acta Medica Iranica, 2012 Helicobacter pylori (H. pylori) is one of the most common chronic infections in patients with gastrointestinal disorders. Recent reports suggested that H. pylori might have high prevalence among patients with diabetes.
Mahshid Talebi-Taher +3 more
doaj
Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer
Frontiers in Oncology, 2019 Dependence on the glutamine pathway is increased in advanced breast cancer cell models and tumors regardless of hormone receptor status or function. While 70% of breast cancers are estrogen receptor positive (ER+) and depend on estrogen signaling for ...
Diane M. Demas +8 more
doaj +1 more source
Chinese Medical Journal, 2020 . Increasing numbers of targeted drugs are used in hormone receptor (HR)-positive metastatic breast cancer (MBC) to overcome or delay resistance to endocrine therapy.
Li Bian +3 more
doaj +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Estrogen receptor co-regulators as prognostic and predictive markers of endocrine therapy in early breast cancer: the role of SMRT and p160 family [PDF]
, 2010 Background: The estrogen receptor (ER) signaling pathway is the dominant driver of cell proliferation and survival in the majority of human breast cancers.
Migliaccio, Ilenia
core +1 more source
Roles for miRNAs in endocrine resistance in breast cancer [PDF]
Endocrine-Related Cancer, 2015 Therapies targeting estrogen receptor alpha (ERα), including selective ER modulators such as tamoxifen, selective ER downregulators such as fulvestrant (ICI 182 780), and aromatase inhibitors such as letrozole, are successfully used in treating breast cancer patients whose initial tumor expresses ERα.
Penn, Muluhngwi, Carolyn M, Klinge
openaire +2 more sources
Endocrine resistant breast cancer: brain metastasis
Exploration of Targeted Anti-tumor Therapy, 2022 Endocrine resistant breast cancer metastasis continues to serve as a significant clinical challenge with high morbidity and mortality for patients. As the number of breast cancer cases continues to rise, the rate of brain metastasis has also increased. For single lesions or a large symptomatic lesion with other smaller lesions, surgical resection is a ...
Matthew Willman +2 more
openaire +3 more sources